Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21946537
Diouf B, et al. (2011) Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 17, 1298-303 21946537
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia
Relevant cell lines - cell types - tissues:  CCRF-CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PIK3C2B (human) increase PIK3C2B shRNA inhibits

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia
Relevant cell lines - cell types - tissues:  CCRF-CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HERC1 (human) increase HERC1 shRNA inhibits
mTOR (human) increase mTOR shRNA inhibits
PIK3C2B (human) increase PIK3C2B shRNA inhibits
rapamycin decrease

T410-p - PKCZ (human)
Modsite: GPGDtTstFCGtPNy SwissProt Entrez-Gene
Orthologous residues
PKCZ (human): T410‑p, PKCZ iso2 (human): T227‑p, PKCZ iso3 (human): T306‑p, PKCZ (mouse): T410‑p, PKCZ (rat): T410‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, T cell leukemia
Relevant cell lines - cell types - tissues:  CCRF-CEM (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic_acid no change compared to control
mTOR (human) increase mTOR shRNA inhibits
okadaic_acid mTOR (human) increase
HERC1 (human) increase HERC1 shRNA inhibits
okadaic_acid HERC1 (human) increase
PIK3C2B (human) increase PIK3C2B shRNA inhibits
okadaic_acid PIK3C2B (human) increase